-

Hologic to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 1:30 p.m. Pacific Time.

The presentation and Q&A session will be webcast live and may be accessed through a link on the Investors section of Hologic’s website at http://investors.hologic.com. The webcast will be available for 30 days following the event.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

SOURCE: Hologic, Inc.

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Industry:

Hologic, Inc.

NASDAQ:HOLX
Release Summary
Hologic to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Release Versions
English
$Cashtags
$HOLX
Hashtags
#JPMC25
#holx

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Social Media Profiles
Hologic Facebook
Hologic Instagram
Hologic LinkedIN
Hologic Twitter
Hologic YouTube
More News From Hologic, Inc.

Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe. Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab...

Hologic Signs Definitive Agreement to Acquire Reveal Genomics

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, a global leader in women’s health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Breast cancer remains one of the most significant health challenges women face today. Revea...

More Than One in Three U.S. Women Have Skipped or Delayed a Recommended Mammogram

MARLBOROUGH, Mass.--(BUSINESS WIRE)--More Than One in Three U.S. Women Have Skipped or Delayed a Recommended Mammogram Based on a New Survey of 1,000 Women...
Back to Newsroom